Caremo was honored with “Top 20 Chinese R&D CRO Enterprises in 2024 ” award

On July 4, the "2024 China Pharmaceutical R&D Competitiveness Ranking" series lists, selected by the Organizing Committee of China Pharmaceutical R&D and Innovation Summit and the 2024 China Pharmaceutical R&D Competitiveness Ranking Expert Committee, were grandly unveiled at the Xiong'an Convention and Exhibition Center. Nanjing Caremo Biomedical Co., Ltd. was honored with the "Top 20 Chinese CRO Enterprises in 2024" award.

To discover and promote innovative forces driving pharmaceutical R&D, recognize enterprises making outstanding contributions to the field, and elevate industry-wide emphasis on R&D innovation, the 2024 China Pharmaceutical R&D Strength Rankings series marks the ninth edition of this prestigious list since its inception in 2016. The 2024 Top 20 CRO Companies in China’s Pharmaceutical Industry was rigorously evaluated based on ten criteria: annual total revenue, revenue growth, net profit, net profit growth, R&D investment, R&D investment growth, workforce size, workforce expansion, brand recognition, and leadership in specialized sectors. This accolade represents the pinnacle of achievement in China’s pharmaceutical CRO industry.

This recognition acknowledges Caremo's professional technical capabilities and rapid growth trajectory. Caremo remains committed to its mission of "Born for health，Empowered for Innovation." By leveraging core technologies to bridge the entire pipeline of both innovative and generic drug development, the company implements a dual-driven strategy that integrates cutting-edge R&D with industrial translation. Guided by research excellence and industrialization goals, Caremo delivers tailored R&D and manufacturing solutions.

Looking ahead, Caremo aims to collaborate with global biotechnology and pharmaceutical partners across the entire drug development value chain, from target validation to commercialization. By addressing diverse client needs and embracing flexible partnership models, the company strives to build a comprehensive, integrated, and end-to-end platform for drug discovery and manufacturing services. This platform will provide holistic technological and industrial support, advancing innovation and commercialization for the global biopharmaceutical industry.